Trastuzumab emtansine: Tumor-Activated Prodrug (TAP) immunoconjugate oncolytic

Drugs of the Future

Volumn 36, Issue 11, 2011, Pages 825-834

  Kumler I ^a   Ehlers Mortensen, C ^b   Nielsen, D L ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Risghospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; R 3502; RG 3502; TAXANE DERIVATIVE; TDM 1; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CELLULITIS; DRUG CONJUGATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

EID: 84952985651     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.11.1711891     Document Type: Article

References (50)

1. Witton, C.J., Reeves, J.R., Going, J.J., Cooke, T.G., Bartlett, J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200(3): 290-7. (Pubitemid 36827302)
2. Dawood, S., Broglio, K., Buzdar, A.U., Hortobagyi, G.N., Giordano, S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 2010, 28(1): 92-8.
3. Rosen L.S., Ashurst, H., Chap, L. Targeting signal transduction pathways in metastatic breast cancer: A comprehensive review. Oncologist 2010, 15(3): 216-35.
4. Graus-Porta, D., Beerli, R.R., Daly, J.M., Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16(7): 1647-55. (Pubitemid 27151960)
5. Nahta, R., Esteva, F.J. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006, 232(2): 123-38. (Pubitemid 43170962)
6. Di Leo, A., Gomez, H.L., Aziz, Z. et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26(34): 5544-52.
7. Seidman, A.D., Berry, D., Cirrincione, C. et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26(10): 1642-9.
8. Yin, W., Jiang, Y., Shen, Z., Shao, Z., Lu, J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 2011, 6(6): e21030.
9. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11): 783-92. (Pubitemid 32222155)
10. Nielsen, D.L., Andersson, M., Kamby, C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35(2): 121-36.
11. Cameron, D., Casey, M., Oliva, C., Newstat, B., Imwalle, B., Geyer, C.E. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. Oncologist 2010, 15(9): 924-34.
12. Geyer, C.E., Forster, J., Lindquist, D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26): 2733-43. (Pubitemid 46021510)
13. Johnston, S., Pippen, J. Jr., Pivot, X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33): 5538-46.
14. Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J.A., Arteaga, C.L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13(16): 4909-19. (Pubitemid 47294799)
15. Fabi, A., Metro, G., Ferretti, G. et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008, 17(5): 499-505.
16. Montemurro, F., Donadio, M., Clavarezza, M. et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006, 11(4): 318-24.
17. Montemurro, F., Faggiuolo, R., Redana, S. et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005, 23(12): 2866-8; discussion 8-9.
18. Tripathy, D., Slamon, D.J., Cobleigh, M. et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22(6): 1063-70. (Pubitemid 41095039)
19. von Minckwitz, G., du Bois, A., Schmidt, M. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009, 27(12): 1999-2006.
20. Blackwell, K.L., Burstein, H.J., Storniolo, A.M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7): 1124-30.
21. Cardoso, F., Senkus-Konefka, E., Fallowfield, L., Costa, A., Castiglione, M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5): v15-9.
22. Ricart, A.D. Immunoconjugates against solid tumors: Mind the gap. Clin Pharmacol Ther 2011, 89(4): 513-23.
23. Alley, S.C., Okeley, N.M., Senter, P.D. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010, 14(4): 529-37.
24. Lewis Phillips, G.D., Li, G., Dugger, D.L. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68(22): 9280-90.
25. Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., Sliwkowski, M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011, 128(2): 347-56.
26. Remillard, S., Rebhun, L.I., Howie, G.A., Kupchan, S.M. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975, 189(4207): 1002-5.
27. Widdison, W.C., Wilhelm, S.D., Cavanagh, E.E. et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006, 49(14): 4392-408. (Pubitemid 44036683)
28. Barok, M., Tanner, M., Koninki, K., Isola, J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011, 13(2): R46.
29. Burris, H.A. Trastuzumab emtansine: A novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011, 11(6): 807-19.
30. Fields, C., Crocker, L.M., Sliwkowski, M.X., Lewis Phillips, G.D. Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 5607.
31. Fields, C., Li, G., Prior, W.W., Parsons, K., Sampath, D., Lewis Phillips, G.D. Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3239.
32. Burris, H.A. 3rd, Rugo, H.S., Vukelja, S.J. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29(4): 398-405.
33. Krop, I.E., Beeram, M., Modi, S. et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16): 2698-704.
34. nd Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-5, Dallas) 2011] 2011, 89(Suppl. 1): S90.
35. nd San Antonio Breast Cancer Symposium (Dec 9-13, San Antonio) 2009, Abst 5099.
36. rd Annu San Antonio Breast Cancer Symp (Dec 8-12, San Antonio) 2010, Abst P3-14-01.
37. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 1029.
38. th ESMO Congr (Oct 8-12, Milan) 2010] 2010, Abst 2770.
39. Hurvitz S, Dirix, L., Kocsis, J. et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450 g/BO21976). Eur J Cancer [2011 ECCO-ESMO-ESTRO Eur Multidisciplinary Cancer Congr (Sept 23-27, Stockholm) 2011] 2011, 47(Suppl. 2): Abst 5001.
40. th ESMO Congr (Oct 8-12, Milan) 2010] 2010, Abst LBA3.
41. th ESMO Congr (Oct 8-12, Milan) 2010] 2010, Abst 2770.
42. Bernard-Marty, C., Lebrun, F., Awada, A., Piccart, M.J. Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions. Drugs 2006, 66(12): 1577-91. (Pubitemid 44373744)
43. Baselga, J., Gelmon, K.A., Verma, S. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28(7): 1138-44.
44. Burstein, H.J., Sun, Y., Dirix, L.Y. et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28(8): 1301-7.
45. Yap, T.A., Vidal, L., Adam, J. et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28(25): 3965-72.
46. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 1023.
47. Isakoff, S.J., Baselga, J. Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011, 29(4): 351-4.
48. Arteaga, C.L. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Clin Cancer Res 2011, 17(15): 4919-21.
49. Modi, S., Stopeck, A., Linden, H. et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17(15): 5132-9.
50. Olson, E.M., Lin, N.U., Dipiro, P.J., Najita, J.S., Krop, I.E., Winer, E.P., Burstein, H.J. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 2011, Epub ahead of print.